Publications Etudes et Recherche en Economie de la Santé 2024-25

• PFMG2025 contributors. PFMG2025-integrating genomic medicine into the national healthcare system in France. Lancet Reg Health Eur 2025
• Fraslin AM, Stockholm T, Filleron T, Bertaut A, Blanc-Lapierre A, Marghadi J, Aupérin A, Bonastre J.
  A microsimulation model based on healthcare pathways to estimate the impact of COVID-19 pandemic-induced delays on breast cancer mortality. Journal of Clinical Epidemiology 2025

Au sein du Bureau Biostatistique et d’Epidémiologie de Gustave Roussy et de l’équipe de recherche Oncostat « Méthodologie et épidémiologie clinique en oncologie moléculaire », nos missions sont de :

A research with strong societal impact integrated with care

Research at Gustave Roussy meets society's needs related to cancer. It is integrated into care because it is in the context of care that the data on which the research is based are collected from patients, and it is for the care of patients that the results of the research are used. 

Lab members

• ABDELOUAHAB Macine Bachir
• ARCHAMBAUD Baptiste
• AUPERIN Anne
• BAYLE Arnaud
• BENHAMOU Simone
• BLANCHARD Pierre
• BONASTRE Julia
• BORGET Isabelle
• CHALTIEL Dan
• COZIC Nathalie
• DRUBAY Damien
• FARON Matthieu
• FOULON Stéphanie
• FRASLIN ALDERIC
• GHODSSIGHASSEMABADI Robabeh
• IBRAHIMI Nusaïbah
• JONAS Sarah-Flora
• KARIMI Maryam
• KOUDOU Akoli Yves
• LE DELEY Marie-Cécile
• LE TEUFF Gwenael

Publications

• Oncostat Publications 2023 (PDF document)

Oncostat

This group is the Oncostat team of the UMR1018/CESP.

The Oncostat team develops methods for the evaluation of precision medicine in oncology based on the level of evidence.

UMR 1030 - Molecular Radiotherapy and Therapeutic Innovation

UMR 1186 - Integrative tumor immunology and immunotherapy

Our laboratory highlighted several constitutive elements of the tumor environment (TME) involved in the regulation of antitumor T-cell response, in particular: